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Introduction
Unprecedented advances in the treatment of macular diseases over the last decade have prevented vision loss and blindness in many people. The discovery that vascular endothelial growth factor (VEGF) is a major driver of angiogenesis and vascular leak in the eye provided the rationale for phase 3 clinical trials that demonstrated the efficacy of the VEGF inhibitors.
These studies examined ranibizumab (MARINA, ANCHOR) 1, 2 , bevacizumab (CATT) 3, 4 and aflibercept (VIEW 1 and 2) 5 for neovascular age-related macular degeneration (AMD).
Diabetic macular edema and retinal vein occlusion are additional indications for VEGF inhibitors [5] [6] [7] [8] . Intravitreal steroid therapy may also have a role in the treatment of macular edema 9 , particularly as agents formulated for the eye become available (FAME study 10 ).
Clinical trials determine whether new treatments work in highly controlled conditions for a highly selected group of patients that may not be representative of the general patient population with the disease. The high experimental, or internal, validity of a clinical trial comes at a cost of generalizability, or external validity, of its results. An important question, therefore, is whether the promising results of pivotal clinical trials translate to successful patient outcomes in the general patient population under real-life conditions. These questions are best answered by population-based post-marketing observational studies.
Post-marketing surveillance refers to the ongoing evaluation of a drug following its regulatory approval. Growing concerns about the safety of new medicines, and increasing awareness of the potential benefits of using large-scale population-based data to monitor product safety and effectiveness, have placed new emphasis on the late-phase research agenda. Evidence from such research has led to subsequent withdrawal of drugs that had initially seemed promising in phase 3 studies, such as Cerivastatin (Lipobay®) 11, 12 or Rosiglitazone (Avandia ®) 13 . By monitoring the general patient population undergoing varied and individualized treatment regimens, post-marketing observational studies complement earlier clinical trials. They may determine small but significant treatment effects in routine clinical practice by tracking patients for longer and collecting a different, broader set of endpoints including safety, patient preference, quality of life and long-term effectiveness.
The Fight Retinal Blindness! (FRB!) Project has designed an efficient, web-based data collection tool specifically to track the outcomes of treatment of macular disease in routine clinical practice. It is anticipated that this "registry" will allow us to confirm whether outcomes of treatment in routine practice of the new drugs for macular disease are consistent with the promising results observed in the pivotal clinical trials. We will compare different dosing regimens for their ocular safety, long-term effectiveness and patient acceptance. We will also compare the outcomes achieved by each individual drug in various clinical settings.
The system will allow individual physicians to review of their own data and compare their own results against national benchmarks. In the present article we describe the principles of design and development of this tool.
Methods

Structure of the FRB! Project
The FRB! Project consists of a Steering Committee, an Executive Committee, a Publishing
Committee and User groups. The Steering Committee, which is elected at an annual meeting of Users in each country, oversees the general development of the project, data analysis and publication, and coordination of the different interests and requests from the User groups.
The publishing committee monitors publications and adherence to the participation and publishing guidelines. The User groups are responsible for the development of new modules or the modification of existing modules. For the purposes of this manuscript "Users" are those entering data with the software, while "Participants" are those whose outcomes are tracked.
Software and System Design
Since the high prevalence of neovascular AMD has rendered many retinal practices very busy, it was felt critically important to reduce the load of data capture by clinicians.
Therefore, the choice of data fields was guided by parsimony, validity and focus on achieving the registry's purpose to track and evaluate current and emerging treatments for macular disease in routine practice after they have been approved 14 . Trialing a system with a large range of data fields in 1 non-academic and 3 academic retinal practices revealed the minimum data fields that practitioners would consistently complete. Demographic data along with Logarithm of the Minimum Angle of Resolution (LogMAR) visual acuity and intraocular pressure may be entered by clinical assistants. All other fields must be entered by the treating physician.
Quality assurance measures were included to ensure that only verified and high quality data are entered into the system. Data can be "Saved" if not all the mandatory data are available or entered. When all mandatory fields have been filled, the User can "Finalize" the visit, starting a built-in validation process that checks whether all mandatory fields have been completed and that values are within pre-determined ranges, e.g. visual acuity must be between 0 and 100 letters. Only when data are "Finalized" are they available for subsequent analysis and reporting. The system has been designed in such a way that it will not allow a visit to be finalized unless all the fields have been filled and all numerical data fall within pre-specified ranges (validated).
The software used in the FRB! Project consists of modules interacting with a core system.
The core system provides a range of basic functions which are used by each module for patient data management. Each module provides the user with the functionality to capture data for a specific purpose, in the first instance to collect data from patients receiving treatment for neovascular AMD. The core system is modified and changed only under very specific circumstances which have been approved by the Steering Committee. Each user and user group, however, may create or change modules which they can share with other users should they be interested. Each registered FRB! Project user can use the full scope of the software or select only modules that fit their needs.
The FRB! software is a web-based application which was developed using freely available software such as Apache, MySQL, PHP and RubyonRails. This approach allows the application to be run on different server operating systems. Any device with internet access and a recent browser can be used to interact with the application.
There are two ways of entering data into the FRB! system: via a web-interface or via a thirdparty software interface. If the User has no electronic patient management system, the independent web-based application, which can be accessed from a wide range of devices and operating systems (e.g. Windows-PC, Macintosh, tablet computer, mobile phone), can be used with a regular browser (e.g. Safari, Internet Explorer, Firefox, Opera). Additional software on the user's terminal is not required. If the user has an electronic patient management system, this can be modified so that data can be automatically transmitted electronically to the project database, thus simplifying and expediting the process for the user through single-point data entry.
Participant-reported outcomes (PRO) are collected using instruments such as the Impact of Vision Impairment questionnaire 16 . Responses are collected using a specially adapted application for tablet computers catering for the special needs of the visually impaired, enabling participants to choose color schemes and font sizes. Data acquired using a tablet are transmitted directly to the FRB! database for further analysis. The collection of PROs will facilitate studies to determine whether improvements in visual acuity measured on a chart are associated with improvement in visual function and participant wellbeing.
Data anonymity and security
The FRB! Project software is designed to provide maximum data security and anonymity.
Users can enter patient data into the respective module of the FRB! software in an 
Ethical Considerations
Activities conducted by a health care provider which aim to monitor, evaluate or improve the quality of care provided are quality assurance (QA) studies. The Australian Health Ethics Committee (AHEC) considers that QA activities are an essential and integral part of health care delivery that should be encouraged and facilitated 17 . Quality assurance includes quality improvement (QI) activities such as medical, clinical and record audit and observational studies, to which the ethical principles of research apply. Clinical registries are established and operated with the aim of improving patient care and outcomes through greater understanding of events, treatments and outcomes 18 , thus meeting the definition of a QA activity.
A unique, computer-generated string is assigned to a patient automatically when their details are first entered into the system. This string makes the patient unique in the database; it is not visible to the User. It is linked to the User/s own practice identifiers for each patient. When the User subsequently enters follow-up data, the practice identifier for that User can be selected to create a follow-up visit. As an additional measure to ensure that the right data are being entered for the right patient, initials and date of birth are shown.
Data registries must satisfy relevant regulations and the requirements of the appropriate Documentation of HREC approval from each centre is copied to the central governing office to ensure currency of approval is maintained.
Data Export
Since the FRB! Project software is designed to be a research tool, data export and analysis 
Results
Data fields for the neovascular AMD module
The data captured by the FRB! application were kept to a minimum in order to deliver an efficient data collecting tool. As a result of our experience with the first version, which had a large number of fields for characteristics such as disease activity, a refined set of data elements were chosen such that an Index visit could be entered in less than 30 seconds and a follow-up visit in less than 15 seconds. Version 5 of the neovascular AMD module has been operational since May 2010. The data fields for the Index visit for this module are shown in Table 1 . Table 2 shows the fields for a follow-up visit.
Graphical Displays
The software displays graphically visual acuity and respective treatments given over time 
Uptake and usage
Use of the FRB! software has steadily gained momentum. Currently 13 centers in Australia, one in New Zealand, and one in Europe are contributing data. LogMar visual acuity was measured by 8 users, who tended to be from the larger, academic centers, while 5 Users, more from smaller, private practices, measured Snellen visual acuity which they transferred to LogMAR letters using a chart that is available on the data entry screen. RANZCO has accredited the FRB! software application as a self-audit tool that can be used to gain points under the clinical audit section of their continuing professional development program.
Participant characteristics
Finalized data from 2,052 eyes of 1,693 participants were available for this analysis. Thirteen "Thirteen Users contributed data, median 104 eyes (range: 26 to 304). While the proportion of eligible patients that the User tracked with the system was not audited, it was specified in the Users' agreement that data should be entered on at least 85% of patients in the User's practice that are eligible to have their data included. This is also a condition for Users (others 1.8%).
Discussion
In response to the unmet need for post-marketing observational studies of the emerging treatments for macular disease, we have created an efficient, web-based system to collect high quality outcome data from routine clinical practice. The system has been designed to extract the maximum amount of information from a minimal dataset to produce benefits for all stakeholders. While post-marketing observational studies produce data which are not as clean as those from randomized clinical trials, "registries can be more evidence-based than the traditional framework of randomised controlled trials for care improvement." 21 An important principle in registry design is to reduce the load of data entry 14 Corneal Graft Registry, established in 1986, tracked around 15,000 penetrating corneal grafts to find that the success rate fell from 87% at one year to 46% 15 years after surgery 27 .
We have taken steps to minimize a number of potential biases that may affect observational studies 14 . "Information bias", in which Users may misreport the outcome of an intervention if they have a vested interest in doing so, is avoided by making User data available only to the individual User. This also reduces "selection bias", by which Users enrol only patients who have a low risk of complications. "Channelling bias" may occur when drugs with similar therapeutic indications are prescribed to groups of patients with prognostic differences, such as those who have failed first line treatment. Our system therefore includes all possible interventions for the condition being audited, and collects data on previous treatments. Loss to follow-up can be a concern if it is non-random. To reduce the incidence of this we have established a referral function within the system so that participants' data can be transferred seamlessly from one service provider to another as long as they are both participating in the project.
We have described here the principles of development of a software tool that forms the basis of a registry for the outcomes of treatment of macular disease. This will allow us to analyse a number of important, potentially modifiable variables, such as the effect of different treatment patterns on visual outcomes. New treatments will be evaluated as they are introduced into practice. Participation in the project, which is expected to be organised along national lines, remains open and free to individual users. 
